Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.

Oncotarget - 24 Nov 2015

Hanly Elyse K, Bednarczyk Robert B, Tuli Neha Y, Moscatello Augustine L, Halicka H Dorota, Li Jiangwei, Geliebter Jan, Darzynkiewicz Zbigniew, Tiwari Raj K

Abstract excerpt

Treatment options for advanced metastatic thyroid cancer patients are limited. Vemurafenib, a BRAFV600E inhibitor, has shown promise in clinical trials although cellular resistance occurs. Combination therapy that includes BRAFV600E inhibition and avoids resistance is a clinical need. We used an in vitro model to examine combination treatment with vemurafenib and mammalian target of rapamycin (mTOR) inhibitors,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypoglycemic Agents

Share to Metformin

Share to Sirolimus

Share to Sulfonamides

Share to TOR Serine-Threonine Kinases

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 26284586
DOI: 10.18632/oncotarget.4052
PMCID: PMC4741856

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.PMID 26284586Read ↗

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.Semantic proximity Read ↗

Synergistic Effect of Metformin and Vemurufenib (PLX4032) as a Molecular Targeted Therapy in Anaplastic Thyroid Cancer – An In Vitro StudySemantic proximity Read ↗

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.Semantic proximity Read ↗

Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAFV600E to Vemurafenib by Bim upregulation.Semantic proximity Read ↗

Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.Semantic proximity Read ↗

BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.Semantic proximity Read ↗

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancerSemantic proximity Read ↗

Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.Semantic proximity Read ↗

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Semantic proximity Read ↗

Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.Semantic proximity Read ↗

Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.Semantic proximity Read ↗

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.